NSC354961 MedChemExpress (MCE)

Product Name	MYCMI-6
Synonyms	MYCMI-6;NSC354961;MYCMI-6(NSC 354961);3-((9-Amino-7-ethoxyacridin-3-yl)diazenyl)pyridine-2,6-diamine;2,6-Pyridinediamine, 3-[2-(9-amino-7-ethoxy-3-acridinyl)diazenyl]-
CAS	681282-09-7
EINECS
Chemical Formula	C20H19N7O
Molecular Weight	373.41
inchi
Package	5 mg;10 mg;25 mg;50 mg;100 mg
Price	Email to quote
Descriptions	MYCMI-6 MYCMI-6 MedChemExpress (MCE) HY-124675 681282-09-7 NSC354961 98.14% Powder -20°C 3 years 4°C 2 years In solvent -80°C 1 year -20°C 6 months Room temperature in continental US Descriptions MYCMI-6 MYCMI-6 MedChemExpress (MCE) HY-124675 681282-09-7 NSC354961 98.14% Powder -20°C 3 years 4°C 2 years In solvent -80°C 1 year -20°C 6 months Room temperature in continental US may vary elsewhere. MYCMI-6 (NSC354961) is a potent and selective endogenous MYC:MAX protein interactions inhibitor. MYCMI-6 blocks MYC-driven transcription and binds selectively to the MYC bHLHZip domain with a Kd of 1.6 μM. MYCMI-6 inhibits tumor cell growth in a MYC-dependent manner (IC50apoptosis. MYCMI-6 (NSC354961) (6.25 μM 48 hours) selectively suppresses MYC-driven tumor cell growth with high efficacy[1]. MYCMI-6 significantly inhibits growth of Burkitt’s lymphoma cells (Mutu, Daudi and ST486) - another classical example of a MYC-driven tumor, having translocations of MYC to one of the immunoglobulin loci - in a dose-dependent manner with an average GI50 of 0.5 μM. Treatment of MCF7 cells with the MYCMI-6 for 24 hours significantly decreased MYC:MAX isPLA signals to 7%. Titration showed an IC50 for inhibition of MYC:MAX of less than 1.5 μM for MYCMI-6 by isPLA. MYCMI-6 inhibits the MYC:MAX heterodimer formation with an IC50 of 3.8 μM. MYCMI-6 efficiently inhibits anchorage-independent growth of MYCN-amplified neuroblastoma cells with GI50 values of [1]. MYCMI-6 (20 mg/kg i.p. daily for 1-2 weeks) induces massive apoptosis and reduces tumor cell proliferation, tumor microvasculature density and MYC:MAX interaction in a MYC-dependent xenograft tumor model[1]. \| \| \| \| \| \| \| \| \| \| [1]. Castell A, et al. A selective high affinity MYC-binding compound inhibits MYC:MAX interaction and MYC-dependent tumor cell proliferation. Sci Rep. 2018 Jul 3 8(1):10064. [Content Brief]
Supplier Website	https://www.medchemexpress.com/mycmi-6.html
Last Update	2025-05-21 16:50:25

MedChemExpress (MCE) also provides

Thalidomide-4-O-C2-NH2

Category: Signaling Pathways
CAS: 2341840-99-9
Last Update: 2025-05-21 16:50:25

PPARα-MO-1

Category: Signaling Pathways
CAS: 810677-36-2
Last Update: 2025-05-21 16:50:25

Netupitant N-oxide

Category: Signaling Pathways
CAS: 910808-11-6
Last Update: 2025-05-21 16:50:25

MK-0812

Category: Signaling Pathways
CAS: 624733-88-6
Last Update: 2025-05-21 16:50:25

TS-011

Category: Signaling Pathways
CAS: 339071-18-0
Last Update: 2025-05-21 16:50:25

SCH 530348 sulfate

Category: Signaling Pathways
CAS: 705260-08-8
Last Update: 2025-05-21 16:50:25

BAG 956

Category: Signaling Pathways
CAS: 853910-02-8
Last Update: 2025-05-21 16:50:25

YM758

Category: Signaling Pathways
CAS: 312752-85-5
Last Update: 2025-05-21 16:50:25


Supplier Name	MedChemExpress (MCE)
Contact	sales
Tel	609-228-6898
Mobile	609-228-6898
QQ
Email	sales@medchemexpress.com; tech@medchemexpress.com
Website	https://www.medchemexpress.com/
Wechat

Request for quotation

Supplier Contact